Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy?
Department of Internal Medicine, Rheumatology and Gastroenterology, 'Nuovo Regina Margherita' Hospital, Rome, Italy.
Vincenzo
V
Bruzzese
Cinzia
C
Marrese
Palma
P
Scolieri
Cesare
C
Hassan
Roberto
R
Lorenzetti
Angelo
A
Zullo
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001688:Biological Products / Q000009:adverse effects*; D057915:Drug Substitution; D000068800:Etanercept / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D012074:Remission Induction; D012307:Risk Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept